Work

EE262 Indirect Cost Burden for Individuals Living with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Europe

Year: 2023

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2023.09.529

Authors: L. Lilly, J. Drahos, A. Boateng-Kuffour, M. Calvert, A. Valentine, A. Mason, N. Li, Z. Pakbaz, F. Shah, N. Ainsworth, C. Udeze, A. Martin

Institutions: Vertex Pharmaceuticals (United States), University of Birmingham, Sickle Cell Institute Chhattisgarh, Raipur, University of California, Irvine, NHS Blood and Transplant

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4390126309

Cites:

Cited by:

Related to: 10